Professor Elgene Lim

2017-27

NBCF Endowed Chair (Co funded by Garvan Institute) ($5,000,000). Role CIA

2019-21

Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer. APP IIRS-19-054. NBCF (CIA Caldon). ($582,432) Role: CIB

2018-21

Transforming endocrine therapy for breast and prostate cancer. MNBCF Collaborative Research Initiative (CIA Tilley) ($2,500,000). Role: CID

2018-21

Pushing AR toward better outcomes in breast and prostate cancers. APP 1145777. NHMRC Project Grant (CIA Tilley) (A$1,000,000). Role: CIE

2018-21

Reactivating p53 to combat CDK4/6 inhibitor resistance in ER positive Breast Cancer. St Vincent’s Clinic Foundation ($40,000) Role: CIA.

2019-20

Targeting the p53 pathway in the age of CDK4/6 inhibitor resistant ER+ breast cancer. APP IIRS-19-053. NBCF (CIA Portman). ($197,825). Role: CIB.

2017-20

Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer. APP 1123057. NHMRC Project Grant (CIA Haupt) (A$800,000). Role: CIC

2017-20

Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer. APP 1128916.  NHMRC Project Grant (CIA Clark) (A$828,559.50). Role: CIC

2017-20

The clinical significance of sex hormone crosstalk in ER+ breast cancer. APP 1130077. NHMRC Project Grant (CIA Tilley) (A$1,009,006). Role: CIC

2017-9

Evaluating ODM201, an AR degrader, in breast cancer. Bayer Pharm (A$200,000). Role CIA.

2017-9

Progesterone as an anticancer therapy in early breast cancer. RG 17-08. Cancer Council of New South Wales Project Grant (A$450,000). Role: CIA

Past

2017-8

2016-8

Metabolic effects of exercise on breast cancer. Thelma Greig Cancer Grant. St Vincent’s Clinic Foundation (A$50,000). Role: CIA.

A novel approach to overcome therapy-resistance in breast cancer. APP 1107170. Cancer Australia. (A$600,000). Role: CIA.

2016-7

Identification of breast cancer subtype-specific tumour antigens using the local immune response. NBCF (A$200,000). Role: CIA.

2016-7

Evaluating MDM2 inhibitors in breast cancer. Novartis Australia (A$51,000). Role: CIA.

2014-7

Sensitizing breast cancers to hormone receptor-directed therapies. NBCF & Victorian Cancer Agency Practitioner Fellowship (A$800,000). Role: CIA

2015-6

Targeting the p53 pathway in ER-positive breast cancer. Australia New Zealand Breast Cancer Trialist Group (A$91,600). Role: CIA.

2014-5

Evaluation of concurrent chemoendocrine therapy and predictive biomarkers for HR+ breast cancer. Ramaciotti Award, Perpetual Trustees Australia (A$75,000). Role: CIA.

2013-4

Exploiting DNA repair deficits in non BRCA mutation associated breast cancer. Cancer Research Grant, Pfizer Australia (A$50,000). Role: CIA.

2011-4

The identification of novel treatments for poor prognosis subgroups of breast cancer. NHMRC Overseas Postdoctoral Fellowship (A$360,000). Role: CIA.

2010

Fulbright Victoria Fellowship. (A$25,000). Role: CIA.

2006-9

White/Zaal PhD scholarship. NBCF (A$105,000). Role: CIA.

2008

Characterization of human mammary stem and progenitor cells. Postgraduate Research award, GlaxoSmithKline Australia (A$25,000) Role: CIA.

2007

Characterization of human mammary stem and progenitor cells. Career development award, Clinical Oncological Society of Australia (A$50,000) Role: CIA.